共 43 条
[1]
Avril N., Rose C.A., Schelling M., Dose J., Kuhn W., Bense S., Weber W., Ziegler S., Graeff H., Schwaiger M., Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations, J Clin Oncol, 18, pp. 3495-3502, (2000)
[2]
Danforth Jr. D.N., Aloj L., Carrasquillo J.A., Bacharach S.L., Chow C., Zujewski J., Whatley M., Galen B., Merino M., Neumann R.D., The role of <sup>18</sup>F-FDG-PET in the local/regional evaluation of women with breast cancer, Breast Cancer Res Treat, 75, pp. 135-146, (2002)
[3]
Van Dongen J.A., Voogd A.C., Fentiman I.S., Legrand C., Sylvester R.J., Tong D., Van Der Schueren E., Helle P.A., Van Zijl K., Bartelink H., Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial, J Natl Cancer Inst, 19, pp. 1143-1150, (2000)
[4]
Grunfeld E., Mant D., Yudkin P., Dalton R.A., Cole D., Stewart J., Fitzpatrick R., Vessey M., Routine follow-up for breast cancer in primary care: Randomised trial, BMJ, 13, pp. 665-669, (1996)
[5]
Hathaway P.B., Mankoff D.A., Maravilla K.R., Austin-Seymour M.M., Ellis G.K., Gralow J.R., Cortese A.A., Hayes C.E., Moe R.E., Value of combined FDG PET and MRI imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience, Radiology, 210, pp. 807-814, (1999)
[6]
Schirrmeister H., Kuhn T., Guhlmann A., Santjohanser C., Horster T., Nussle K., Koretz K., Glatting G., Rieber A., Kreienberg R., Buck A.C., Reske S.N., Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures, Eur J Nucl Med, 28, pp. 351-358, (2001)
[7]
Dose J., Bleckmann C., Bachmann S., Bohuslavizki K.H., Berger J., Jenicke L., Habermann C.R., Janicke F., Comparison of fluorodeoxyglucose positron emission tomography and conventional diagnostic procedures for the detection of distant metastases in breast cancer patients, Nucl Med Commun, 23, pp. 857-864, (2002)
[8]
Ohta M., Tokuda Y., Suzuki Y., Kubota M., Makuuchi H., Tajima T., Nasu S., Suzuki Y., Yasuda S., Shohtsu A., Whole body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with <sup>99</sup>Tc<sup>m</sup>-MDP bone scintigraphy, Nucl Med Commun, 22, pp. 875-879, (2001)
[9]
Yang S.N., Liang J.A., Lin F.J., Kao C.H., Lin C.C., Lee C.C., Comparing whole body <sup>18</sup>F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer, J Cancer Res Clin Oncol, 128, pp. 325-328, (2002)
[10]
Hayes D.F., Bast R.C., Desch C.E., Fritsche Jr. H., Kemeny N.E., Jessup J.M., Locker G.Y., Macdonald J.S., Mennel R.G., Norton L., Ravdin P., Taube S., Winn R.J., Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers, J Natl Cancer Inst, 88, pp. 1456-1466, (1996)